News
DHR
248.38
+0.62%
1.54
Markel (MKL) Q1 Earnings, Revenues Miss Estimates, Rise Y/Y
NASDAQ · 1d ago
It's Unlikely That Danaher Corporation's (NYSE:DHR) CEO Will See A Huge Pay Rise This Year
Danaher Corporation will host its Annual General Meeting on 7th of May. CEO Rainer Blair's overall pay is 126% above the industry average. Over the past three years, Danaher's earnings per share has fallen by 5.3%. The company has a total shareholder return of 9.9% over the last three years. The company paid CEO compensation of US$21m in the last year.
Simply Wall St · 3d ago
Fortive Corporation: Growing Into The Valuation
Fortive Corporation is a collection of high-quality, high-growth and profitable businesses. The company was spun off from Danaher in 2016 and has ambitious midterm targets. Shares of Fortive have been trading stagnant, but with a more reasonable valuation at 19-20 times earnings, there may be potential for investment at dips.
Seeking Alpha · 5d ago
See Which Of The Latest 13F Filers Holds Danaher
NASDAQ · 5d ago
Weekly Report: what happened at DHR last week (0422-0426)?
Weekly Report · 5d ago
What Should You Do With Danaher Stock At $250 After Q1 Beat?
NASDAQ · 6d ago
Danaher Corporation: A Good Medium Term Bet
Danaher Corporation's core sales growth rate is expected to turn positive as 2024 progresses. Margins are expected to improve with easing comparisons, cost-cutting, and operating leverage as sales recover. Valuation is reasonable on FY25 and FY26 consensus earnings estimates. The company is close to inventory destocking in the bioprocessing business and improving order trends.
Seeking Alpha · 04/27 16:08
3 Stocks to Buy With Multiple Unusually Active Options Worth Considering
NASDAQ · 04/26 18:47
ABT, DHR, DXCM: Which “Strong Buy” Healthcare Stock Has More Upside?
TipRanks · 04/26 16:09
Noteworthy ETF Inflows: IWD, ABT, VZ, DHR
NASDAQ · 04/26 15:58
Buy Rating on Danaher: Strong Biotech Performance and Growth Potential Despite Market Challenges
TipRanks · 04/26 06:06
Danaher Q1: The Worst Time Has Already Passed
Danaher Corporation stock has surged by 16% since our "Strong Buy" rating in June 2023. The bioprocessing industry is facing near-term challenges, but long-term growth prospects remain strong. Danaher's organic revenue declined by 4% in Q1 FY24, driven by weak growth in biotechnology and life sciences. The company's strong leadership and role in the biotech industry inspire confidence.
Seeking Alpha · 04/25 21:01
Honeywell (HON) Q1 Earnings Beat, Aerospace Sales Rise Y/Y
NASDAQ · 04/25 16:29
The Zacks Analyst Blog Highlights Danaher, Regeneron Pharmaceuticals, Palo Alto Networks, Workday and American Electric Power
NASDAQ · 04/25 12:44
Danaher First Quarter 2024 Earnings: Beats Expectations
Danaher's revenue exceeded analyst estimates by 3.1%. The company's shares are up 4.6% from a week ago. Revenue is forecast to grow 6.4% in the next 3 years. Danaher reported its first quarter 2024 results on April 25th.
Simply Wall St · 04/25 10:33
Value Vs. Growth? Danaher Says Why Not Both?
Danaher Corporation is one of the world's biggest healthcare/biotech/life sciences suppliers. The company has shown resilience and strength in its core businesses despite post-pandemic growth challenges. Danaher's shares are up 3.4%, beating the S&P 500, after its quarterly earnings report. While the company's valuation is high, Danaher benefits from secular growth trends.
Seeking Alpha · 04/25 07:21
Top Stock Reports for Danaher, Regeneron Pharmaceuticals & Palo Alto Networks
NASDAQ · 04/24 19:51
Danaher Is Maintained at Buy by Citigroup
Dow Jones · 04/24 18:22
Danaher Price Target Raised to $290.00/Share From $280.00 by Citigroup
Dow Jones · 04/24 18:22
More
Webull provides a variety of real-time DHR stock news. You can receive the latest news about Danaher Corporation through multiple platforms. This information may help you make smarter investment decisions.
About DHR
Danaher Corporation is a global life sciences and diagnostics innovator. The Company operates through three business segments: Biotechnology, Life Sciences and Diagnostics. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a broad range of equipment, consumables and services that are primarily used by customers to advance and accelerate the research, development, manufacture and delivery of biological medicines. The Life Sciences segment offers a range of instruments, consumables, services and software that are primarily used by customers to study genomics and the basic building blocks of life, including deoxyribonucleic acid (DNA)and ribonucleic acid (RNA), nucleic acid, proteins, metabolites and cells. The Diagnostics segment offers clinical instruments, consumables, software and services that hospitals, physicians’ offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions.